Organ-On A Chip Market

Global Organ-on-Chip Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2028: The requirement for alternatives for animal testing, the need for early detection of drug toxicity, and rising technological advancements are some of the major factors driving the growth of the Global Organ-on-Chip Market.

Global Organ-on-Chip Market is valued at USD 12.8 Billion in 2021 and is expected to reach USD 36.6 Billion by 2028 with a CAGR of 16.2% over the forecast period.

Scope-

Artificial organs that resemble human organs are known as human organs-on-chip. It is a multiplexed 3D micro-fluidic cultured cells device that elicits physiological responses from organs and activates their systems. As a consequence of the capacity of researchers to evaluate human physiology in an organ-specific habitat utilizing labs-on-chips (LOCs) and cell biology, a novel model of in vitro multicellular human organisms has been created.

The heart, brain, liver, lungs, and intestines are just a few of the organs that this chip opens a little passageway through. These microchip-based devices have chambers that are continuously perfused with live cells and are set up to activate physiology at the levels of the organs and tissues. The market for organs on chips is driven by a number of causes, including the demand for alternatives to animal testing, the necessity for early medication toxicity detection, new product introductions, and technological improvements.

The biopharmaceutical sector and the scientific community have acted quickly against the COVID-19 epidemic. Therefore, it is established that organ-on-chip is one of the most promising and preferred technologies for developing vaccines and medications that are now undergoing clinical investigations for the treatment of infection. For instance, the mimic lung chip was utilized to give preclinical insights into the effectiveness of hydroxychloroquine for COVID-19 in March 2020 as part of the World Health Organization's (WHO) Development and Research Blueprint response to the COVID-19 epidemic.

The global Organ-on-Chip market is segmented based on the organ type, application, end-user, and region & country level. Based on organ type, the global Organ-on-Chip market is segmented into Liver, Heart, Lung, and Other. By application, the market is segmented into drug discovery, toxicology research, and others. By end-user, the global Organ-on-Chip market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and others.

The regions covered in the global Organ-on-Chip market report are North America, Europe, Asia-Pacific, Latin America, and the rest of the World. Based on country level, the market of global Organ-on-Chip is sub divided into U.S., Mexico, Canada, U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players-

Some major key players for the global Organ-on-Chip market report cover prominent players like -

• BICO Group AB(Visikol)
• AxoSim Technologies LLC
• Elveflow
• CN Bio Innovations Limited
• Insphero AG
• Emulate Inc.
• Nortis Inc.
• Mimetas B.V.
• Tara Biosystems
• Organovo Holdings Inc.
• others

Segmentation-

By Organ Type:

• Liver
• Heart
• Lung
• Other

By Application:

• Drug Discovery
• Toxicology Research
• Others

By End-User:

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Others

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

The requirement for alternatives for animal testing, the need for early detection of drug toxicity, and rising technological advancements are some of the major factors driving the growth of the Global Organ-on-Chip Market Growth

The global market for organ-on-chips is mainly driven by an increase in demand for organ-on-chip gadgets in the healthcare sector and an increase in the number of clinical trials, as well as the numerous benefits it provides in successful clinical development, such as comparing studies between animals and humans, replacing animal cells, studying the toxicity of cosmetics and drugs, developing vaccines and drugs to counter bioterrorism dangers, and so on. Various recent technical improvements are occurring, and the number of vaccine and medicine inventions is rising; hence, clinical trials are expanding as well.

For example, in June 2022, Labcorp, a life science corporation, revealed its newest relationship with Tigerlily Foundation, a breast cancer awareness group. This agreement will broaden the range of clinical studies available to women of colour. Labcorp has also signed Tigerlily's Inclusive Pledge for Black Women and followed a number of other life science and healthcare firms.

The worldwide organ-on-chip market is being driven by an increase in its healthcare applications, an increase in demand for drug screening, and a rise in the need for lung-based organ cultures and kidney applications. Increased use of organ-on-chip devices for novel medication development instead of animal testing is projected to significantly enhance the organ-on-chip market in the coming years.

Furthermore, a rise in the demand for organ-on-chip technologies in the healthcare sector is likely to drive the worldwide organ-on-chip market. Some of the uses of organ-on-chip technologies in the healthcare sector include real-time imaging, in vitro investigation of genetic, biochemical, and metabolic activities of live cells in a functioning tissue. Advances in microfabrication, cell biology, and microfluidics have increased the acceptance of organ-on-chips, propelling the organ-on-chip market's rise.

The need for organ-on-chips in drug screening, as well as the desire for lung- and kidney-based organ culture devices, is likely to drive the organ-on-chip market. Furthermore, the scarcity of donor organs and the availability of laboratory-engineered functioning organs are projected to be a significant benefit in meeting the rising demand for organ transplantation. However, the expensive cost of the organ chip device, as well as the development of organ-on-chip (OOC) technology, are projected to limit market growth. Conversely, a significant growth in global healthcare spending has contributed to an expansion in the size of the organ-on-chip business. The organ-on-chip sector has a lot of promise in emerging nations. The need for these items is predicted to rise in the coming years due to a high demand for organ transplantation, an increase in the number of chronic illnesses, and an increase in animal testing for drug development.

North America is expected to dominate the global organ-on-chip market.

North America leads the global organ-on-chip (OOC) market, owing to an increase in the number of OOC manufacturing businesses and a rise in demand for organ-on-chip models. Furthermore, factors like as increased R&D investment and increased outsourcing of R&D operations are projected to boost the region's Organ-On-Chip market growth.

Furthermore, the increased number of regional clinical trials is driving market expansion. For example, in terms of clinical trials conducted internationally, North America ranks one. Other variables, such as high GDP expenditure on healthcare, boost market expansion. Many significant projects are going on in this area. For example, Emulate Inc., an in vitro advanced model supplier, unveiled its Colon Intestine-Chip for inflammatory intestinal illness research in March 2021. This colon intestinal chip will summarise the operations of human colon cells, improve knowledge of inflammatory causes, and lead to the identification of effective therapeutic targets.

News-

TARA Biosystems is acquired by Valo Health, creating the first vertically integrated cardiac platform of its kind

On April 5, 2022; In order to strengthen its cardiovascular drug development business, Valo Health, a tech firm dedicated to pioneering the drug discovery process, declared that it was buying TARA Biosystems. Valo's breakthroughs in cardiovascular medication research and development will be largely dependent on TARA's 3D heart tissue modeling system and its heart tissue chips.

Colon Intestine-Chip Launched by Emulate to Advance Research on Inflammatory Intestinal Disorders

On May 17, 2022; For researchers looking into inflammatory intestinal illnesses, Emulate, Inc., a top supplier of cutting-edge in vitro models, has introduced the Emulate Colon Intestine-Chip. Scientists will be able to recreate certain functions of human colon cells, learn more about the processes behind inflammation, and look into possible therapeutic targets due to the fully working, the Emulate Colon Intestine-Chip and lab-ready Human Emulation System. The comprehensive model will hasten the discovery of anti-inflammatory medication candidates that are more likely to be successful in the clinic. The business intends to keep creating new Colon Intestine-Chip applications that will help researchers better understand immune cell recruitment and how the gut bacteria influences the epithelial barrier.

Emulate Launches New Gene Therapy Application Enabling Organ-on-a-Chip Technology to Accelerate the Development of Treatments for Genetic Diseases

On September 17, 2022; Emulate Inc., a producer of in vitro models, has unveiled their new use of adeno-associated virus translation for a liver chip that enables researchers to quickly examine the efficiency and safety of adeno-associated viral vectors in a model of the liver that is related to humans. This quickens the development process and aids researchers in their efforts to enhance gene therapy delivery.

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2021:	USD 12.8 Billion
Base year considered	2020
Forecast Period CAGR %:	16.2%
Market Size Expected in 2028:	USD 36.6 Billion
Tables, Charts & Figures:	175
Pages	300
Organ-on a Chip Companies	BICO Group AB(Visikol), AxoSim Technologies LLC, Elveflow, CN Bio Innovations Limited, Insphero AG, Emulate, Inc., Nortis Inc., Mimetas B.V., Tara Biosystems, Organovo Holdings, Inc., and others
Segments Covered	By End-User, By Organ Type, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa